Eunice L. Kwak

TL;DR: These results underscore the potential of mutational profiling to identify CRCs with different natural histories or treatment responses and the adverse significance of BRAF mutation should inform patient selection and stratification in clinical trials.

TL;DR: GEMOX-B showed antitumour activity with tolerable safety in patients with advanced BTCs, and decreases in SUV(max) on 18-fluorodeoxyglucose-PET scans after treatment were associated with disease control and increases in PFS and overall survival.

TL;DR: The use of FOLFIRINOX was associated with conversion to resectability in >20% of patients and the toxicities observed with the use of this regimen raise important questions about how to best treat patients with LAPC.

TL;DR: Initial characterization of clinical acquired resistance mechanisms to combined RAF/EGFR or RAF/MEK combinations identified several MAPK pathway alterations driving resistance by reactivating MAPK signaling, highlighting the critical dependence of BRAF-mutant colorectal cancers onMAPK signaling and offering potential strategies to overcome resistance.

TL;DR: RO4929097 was well tolerated at 270mg on schedule A and at 135 mg on schedule B; the safety of schedule C has not been fully evaluated and further studies are warranted on the basis of a favorable safety profile and preliminary evidence of clinical antitumor activity.